Kornimate/medical-research-clean huggingface dataset:
adaptation of stepps program for addressing emotional dysregulation and self-harming behaviors in penitentiary centers

Conditions: Self Harm

Summary: the overall objective of this study is to assess the feasibility, within the penitentiary centers of catalonia, of adapting the stepps program for addressing and preventing emotional dysregulation and self-harming behaviors through an implementation study.


Eligibility criteria:
inclusion criteria: * men or women deprived of liberty serving sentences in a penitentiary center in catalonia. * presence of self-harming behaviors. * sufficient understanding and proficiency in spanish to participate in the stepps program. * sufficient cognitive competence for study participation. * mental capacity to provide informed consent. exclusion criteria: * inmates under security measures or classified in the first degree of treatment. * inmates with language difficulties. * presence of severe pathologies that may hinder study participation. * inmates with the possibility of imminent release, impending transfers to other penitentiary centers, or pending trial.
a pilot study of diabetes risk reduction program with wic mothers(the special supplemental nutrition program for women, infants, and children) overweight wic mothers

Conditions: Prevention of Weight Gain

Summary: 1) to evaluate treatment fidelity of drrp: study design, training of interventionists, delivery and receipt of the intervention, and application of the intervention in real-life settings; 2) to identify successful strategies for participant recruitment and maintaining active participation; 3) to collect and analyze preliminary indicators of drrp's effect on dietary intake, physical activity, stress responses, and body weight; and 4) to evaluate sample representativeness of the target audience, implementation and acceptability of drrp, and attrition rate.


Eligibility criteria:
inclusion criteria:non-pregnant women between 18 and 34 years old who understood and spoke english and had a measured bmi between 25.0 and 39.9 kg/m2 were eligible for this study. additional inclusion criteria included having a youngest child between 6 weeks and 3.5 years of age enrolled in one of our three collaborating wic locations, not planning to become pregnant or change wic clinics during the study, providing accurate contact information, agreeing to notify researchers with changes in contact information or pregnancy status, willingness to accept randomized participation assignments, being willing to participate in the project for 1.5 years, and consenting to have blood glucose tested via finger stick. exclusion criteria: women with fasting blood glucose greater than 126 mg/dl or random blood glucose greater than 200 mg/dl, self-reported type 1 or 2 diabetes or an eating disorder, or inability to walk more than one block without resting or shortness of breath were excluded. eligible participants provided their individual telephone and address and a telephone number of one back-up contact (relative, friend, or neighbor).
genetic and molecular characteristics of mexican adults with acute myeloid leukemia: a prospective multicentric study.

Conditions: Acute Myeloid Leukemia

Summary: newly diagnosed adults patients with acute myeloid leukemia will be assessed as traditionally by the treating institution using classic clinical, demographic and cytogenetic variables. complementary molecular tests will be performed in the patients included in the study using pcr to detect classic cbf (core binding factor) rearrangements: cbfb-myh11 \[inv(16)(p13;q22), isoforms a, e and d; aml-eto (runx1-runx1t1) (t8;21)(q22;q22). ngs (next generation sequencing) to detect mutations in: flt3-itd and tkd, npm1, cebpa, runx1, tp53, asxl1, idh1, idh2 and kit


Eligibility criteria:
inclusion criteria: * newly diagnosed aml * over 15 years of age * flow cytometry confirmation * candidate for treatment (intensive or not intensive) exclusion criteria: * acute promyelocytic leukemia * mixed phenotype leukemias * isolated myeloid sarcoma * blastic plasmacytoid dendritic cell neoplasm
patellar resurfacing under subvastus approach in total knee arthroplasty

Conditions: Osteoarthritis, Patella Resurfacing

Summary: this study aims to compare the clinical results of patella resurfacing or not under subvastus approach in total knee arthroplasty. even though the excellent results of total knee arthroplasty(tka), there is persistent controversy over whether or not to replace the patella. anterior knee pain continued to be a unsolved problem of tka patients. some surgeons always performed patella resurfacing during total knee arthroplasty but the others didn't do that. it's up to surgeon's preference. there were several studies of patellar resurfacing or not in tka. but previous studies almost have been done under other approach, not a subvastus approach. this study prospectively randomized patients receiving bilateral tka with patellar resurfacing or not in each knee. patients preference and clinical results was investigated in both knee of same patients who received patellar resurfacing or not during minimum 2 year follow up.

the primary objective of this work was to compare pain, stiffness and function between groups at minimum 2 year postoperatively. secondarily, we compared pain, patient preference at minimum 2 year postoperatively. the investigators hypothesized that there would be no difference between the two groups of subjects in the measured outcomes. patients receiving tka were prospectively enrolled before surgery and randomized intraoperatively to either receive patella replacement or not in both knee of same patients. subjects were assessed pre-operatively and at 6 months, 1, 2 years postoperatively for pain, function, and stiffness using a disease-specific (western ontario and mcmaster osteoarthritis index \[womac\]) . other measurements like knee society score, feller's score, patient satisfaction (vas) also checked pre-operatively and at 6 months, 1, 2 years postoperatively.

Eligibility criteria:
inclusion criteria: * patients for total knee arthroplasty * having medicare insurance exclusion criteria: * patients who are not able to cooperate * serious deformity (not suitable for a standard tka prosthesis) * patellar thickness less than 18 mm * prior operation involving the extensor mechanism * rheumatoid arthritis * severe medical disability limiting the ability to walk * revision surgery * knees with predominantly patellofemoral arthrosis
accuracy of computer guided implant placement in edentulous mandible a three-dimensional in vitro study

Conditions: Edentulous Alveolar Ridge; Edentulous Alveolar Ridge In Mandible

Summary: five stryofoam mandibles were included in this study to assess the accuracy of using computer guided surgical stent in placement of dental implants. the mandibles were cbct scanned and imported to 3diagnosys software to implant planning. 8 implants were placed in each mandible virtually, 4 anterior implants and 4 posterior implants were placed. the plan was exported as stl file to be imported to the cad software for designing of the stent. the surgical stent is printed using micro dgp printer and invision tec e-shell 600 clear resin was used. stainless steel sleeves were placed in the surgical guide then placed in ethanol 99% to remove the excess monomer. the stent in placed over the mandible and sequential drilling was done until the desired osteotomies width was approached followed by the placement of the implants. post-operative cbct was done for the mandible including the implants to assess the accuracy, angulation and position of the placed implants


Eligibility criteria:
inclusion criteria: * five styrofoam mandibles exclusion criteria: * no fractures or pathology

Keywords: computer-guided implant placement edentulous mandible 3d printed surgical guide
effects of liposomal bupivacaine for acute pain in hip and femur fractures

Conditions: Femoral Fractures

Summary: this is an investigator-initiated, single-center, randomized, patient blinded, controlled trial. the purpose of this study is to compare the effect of a fascia iliaca compartment block (ficb) using 0.2% ropivacaine vs. liposomal bupivacaine in patients with femur and/or hip fractures admitted to the university of california davis medical center (ucdmc). the primary endpoint will be the total opioid requirements during the 96 hour randomization period with secondary endpoints including total daily opioid requirements for days 1-4, duration of effect and objective pain scores using the numeric rating scale (nrs) during their hospital stay.

in patients with femur or hip fractures, a fascia iliaca compartment block using liposomal bupivacaine will result in less total opioid administration during the randomization period compared to a fascia iliaca compartment block using 0.2% ropivacaine. the long-term goal of this study is to provide pilot information to guide and design larger, multicenter trials which will evaluate the utility and cost-effectiveness of long acting liposomal bupivacaine as an opioid-sparring analgesic strategy in injured trauma patients. ultimately, it is hoped that this information can improve safe and effective narcotic sparing analgesia in the awake, combat casualty, as well as serve as primary steps towards

Eligibility criteria:
inclusion criteria: 1. age ≥18 years ≤ 70 years 2. patient's s/p trauma, with confirmed femur and/or hip fractures with a planned admission to the hospital 3. patient is ambulatory without assistance (e.g. walker, cane, caretaker) prior to incident. exclusion criteria: 1. \>10 hours since presentation to the emergency department 2. history of seizure disorder, recent seizure or a document intra-cranial hemorrhage. 3. central or peripheral neurologic deficit on presentation 4. concern or compartment syndrome 5. associated additional long bone fractures 6. end stage liver failure 7. renal failure requiring dialysis 8. pregnancy or breast feeding 9. prisoners 10. coagulopathy with inr \>1.5 11. use of direct thrombin inhibitors (bivalirudin, argatroban, desirudin, dabigatran etexilate), or direct factor xa inhibitors (rivaroxaban, apixaban, edoxaban) 12. suspected prolonged intubation within first 12 hours secondary to respiratory failure other than peri-procedurally 13. adults unable to consent 14. pediatric patients \<18 years old 15. patients exhibiting signs of shock upon admission, hr \>120 or sbp \<100 mmhg. 16. history of allergic reaction to local anesthetics 17. administration of any other local anesthetic in the 2 hours prior to the study enrollment. 18. distal femur fractures

Keywords: femur fracture, hip fracture, exparel, liposomal bupivacaine
long-term sacral nerve stimulation for irritable bowel syndrome.

Conditions: Irritable Bowel Syndrome

Summary: a recent randomised, controlled, crossover study has shown that sacral nerve stimulation (sns) significantly reduces symptoms and improves quality of life of highly selected patients with irritable bowel syndrome (ibs). relief of ibs symptoms during sns is associated with consistent changes in rectal sensitivity and biomechanical wall properties. the aim of the present study is to evaluate long-term efficacy of sacral nerve stimulation on symptoms and quality of life in patients with ibs in a randomised, placebo-controlled, crossover study.

twenty two patients with ibs-d or ibs-m according to the rome iii criteria, will be enrolled by invitation in the study. having meet inclusion criteria, the patients are first set subsensory for 4 weeks and then randomised to receive either off-subsensory or subsensory-off stimulation in a 4+4-week period. during the pne test the effect of the stimulation is evaluated by specific ibs symptom and quality of life questionnaires (gsrs-ibs and ibs-is) and bowel habit diaries.

Eligibility criteria:
inclusion criteria: * patients who are psychologically stable and suitable for intervention and able to provide informed consent * patients who are diagnosed with ibs according to the rome iii criteria and characterised with ibs-d or ibs-m. * patients who have been treated with sacral nerve stimulation for a minimum of 3 years. exclusion criteria: * other bowel diseases including inflammatory bowel disease * pregnant or breast feeding * patients who are considered unable to follow the planned programme of the study, including mentally illness or physiological instability * patients who are on medication with known influence on gastrointestinal motility including those for thyroid disease, diabetes mellitus, celiac disease and neurological diseases.

Keywords: irritable bowel syndrome sacral nerve stimulation symptoms quality of life
dpp feasibility study of breastfeeding - emoms 2.0

Conditions: Overweight or Obesity; Pregnancy

Summary: the purpose of this study is to investigate the impact of a comprehensive intervention that combines breastfeeding support with a diabetes prevention-based program (dpp) on postpartum weight retention and lactation duration among women with pre-pregnancy overweight or obesity. this intervention, named emoms, is delivered by a certified health coach via a mobile health (mhealth) application.

this study is a randomized controlled trial designed to determine the feasibility and efficacy of a combined breastfeeding, diabetes prevention-based program (dpp) in a cohort of overweight or obese women to be followed during pregnancy through 3 months postpartum. the trial will have two study arms: dpp + breastfeeding (tx1) and usual care (tx2). aim 1: quantify interest in use of the dpp-lactation mobile health (mhealth) application among target population. to accomplish this, we will: (1) measure research engagement including rates of screening, recruitment, and retention among users, especially rural and racially/ethnically diverse women; (2) assess barriers/facilitators to enrollment/retention through surveys and semi-structured in-depth interviews or focus groups; and (3) evaluate intervention uptake, delivery, and adherence via tracking/measuring use of the mhealth app. aim 2: measure weight loss and duration of lactation through 3 months postpartum among target population. to accomplish this, we will measure pre-pregnancy weight, weight at study entry, weight immediately prior to and after delivery, and weight at specific postpartum time points. lactation and infant feeding practices will be measured at similar postpartum time points.

Eligibility criteria:
inclusion criteria: * pregnant * in second trimester or early third trimester * bmi \>/= 25 and \< 35 * at least 18 years old or older * able to read and understand english * able to learn and use a video platform exclusion criteria: * complications related to pregnancy that require emergency care * thyroid disease * multiple gestation * substance abuse within last 3 years * assisted reproductive technology (art)-related pregnancy * current smoker * prior bariatric surgery * in weight-loss program within 3 months of conception * bmi \>/= 35 * unable to attend intervention/ follow-up visits * unwilling to self-monitor data collection * unable to complete intervention * presence of any condition that limits walking * presence of any condition that limits following diet recommendations * pregnancies complicated with fetuses diagnosed with lethal malformations/conditions

Keywords: diabetes prevention breastfeeding lactation support prediabetes
pressure over nasotracheal intubation related nasal alar injury

Conditions: Intubation Complication; Pressure Injury

Summary: nasotracheal intubation can cause injury and hemorrhage of nasal mucosa and nasal alar. the investigators measure the actual pressure at the angle between nasotracheal tube and nasal alar, analyze the relationship of clinical signs and symptoms to build up optimal clinical routines.

while assisting ventilation during general anesthesia or other reasons, patients are often intubated with endotracheal tube to secure airway. endotracheal tube can be placed trans-orally or trans-nasally according to surgical conditions, anatomical considerations and nursing needs. except inadequate cuff pressure related complication, nasotracheal intubation can cause dysfunction of nasal mucosal cilia, injury and hemorrhage of nasal mucosa, turbinate avulsion, obstruction of nasal airway, sinusitis and compression and injury of nasal alar, resulting in local erythema, ischemia, pressure sore, necrosis, tissue damage and may affect appearance. previous studies focus on the process of nasal tracheal intubation, aim to reduce mucosal injury and hemorrhage via specific intubation tool, special endotracheal tube design, lubricant and so on. however, evidences in preventing nasal alar injury are limited, in which injuries are mostly prevented by self-made special endotracheal tube and artificial leather. in general, the etiology of tissue damage is compression pressure exceeding local capillary perfusion pressure, resulting in reduced perfusion, ischemia and necrosis. clinically, health providers prevent the injury by standardized endotracheal tube fixation and/or artificial leather at sites with potential compression. but the extend of the effect of endotracheal tube to trachea mucosa varies, range of pressure affecting capillary perfusion pressure are not yet defined, and no routine monitoring for dermis compression. thus, endotracheal tube related skin damage is an important clinical issue without best standard operating procedure. in this study, the investigators will place a pressure sensor at the angle of nasotracheal tube, measure the actual pressure, define the sites of compression and its pressure, analyze the relationship of clinical signs and symptoms, pressure, and duration of nasotracheal intubation, and build up optimal clinical routines.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical classification i \& ii * patients undergo general anesthesia and receive intratracheal intubation through nose * elective surgery exclusion criteria: * with known nasal injury * already intubation before induction * surgery on the nose * emergent operation

Keywords: nasotracheal intubation nasal alar injury
a study of shr-a1811 in subjects with advanced malignant solid tumors

Conditions: Advanced Solid Tumors

Summary: this is an open-label, two-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of shr-a1811 and preliminary anti-tumor efficacy in her2 expressing or mutated advanced malignant solid tumor subjects.


Eligibility criteria:
inclusion criteria: * advanced/unresectable or metastatic solid tumor with her2 expression or mutation that is refractory to or intolerable with standard treatment, or for which no standard treatment is available * eastern cooperative oncology group (ecog) performance status of 0 or 1 * lvef ≥ 50% by either echo or muga * has adequate renal and hepatic function * female subjects agree not to be pregnant or lactating from beginning of the study screening until 6 months after receiving the last treatment exclusion criteria: * history of clinically significant lung diseases (e.g., interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or suspected to have these diseases by imaging at screening period * known hereditary or acquired bleeding and thrombotic tendency
ivabradine in patients with an unsatisfactory percentage of cardiac resynchronization therapy

Conditions: Heart Failure

Summary: the purpose of this study is to determine the role of ivabradine in cardiac resynchronization recipients with an unsatisfactory percentage biventricular pacing. the study protocol 60 patients with heart failure nyha (new york heart association) ii-iv treated with optimal medical therapy as clinically indicated who received crt-d device more than 3 months ago. patients with biventricular pacing \ 50% of heart rate in device memory \>70 will receive ivabradine. the minimal follow-up of patients in the study will be at least six months.

approximately 30% of crt recipients do not respond to therapy. one of the causes ot that is unsatisfactory percentage of biventricular pacing. patients may loose biventricular pacing because of inadequate sinus tachycardia. ivabradine may prevent inadequate sinus tachycardia and improve quality of live of crt recipients. according to current guidelines ivabradine is recommended in patients with symptomatic heart failure with heart rate at rest \>70. the hypothesis of this study is that ivabradine may increase percentage of biventricular pacing in crt recipients who have unsatisfactory percentage of biventricular pacing and \>50% of heart rate in device memory \>70.

Eligibility criteria:
inclusion criteria: * heart failure nyha ii-iv * left ventricular ejection fraction =\<35% * crt-d implanted over 3 months ago * optimal crt-d parameters * biventricular pacing \<95% despite the optimal parameters of the device * optimal pharmacotherapy with the highest well-tolerated beta-adrenolytic dosage * heart rate at rest below 70 bpm * over 50% of heart rhythm over 70 bpm at interrogation with the device exclusion criteria: * persistent atrial fibrillation/flutter * device associated ineffective resynchronization * contraindications to ivabradine
research on the impact of chronic pelvic pain on endometriosis

Conditions: Chronic Pelvic Pain; Endometriosis

Summary: chronic pelvic pain (cpp) is a common disease with multiple systems and multiple causes. in recent years, the incidence rate of cpp in women has gradually increased. it is a pain symptom that originates from pelvic organs or related structures and lasts for more than 6 months. it is closely related to gynecological diseases such as endometriosis (ems), adenomyosis, pelvic inflammatory disease (pid), uterine leiomyoma, residual ovarian syndrome, pelvic venous congestion syndrome (pcs), etc. but its pathophysiology is very complex and still needs further exploration. recent studies have shown that central sensitization is an important mechanism for the sustained existence of cpp. explore the relationship between chronic pelvic pain and its postoperative outcomes, as well as preoperative endometriosis related questionnaire surveys such as such as endometriosis health profile-30 (ehp-30), central sensitivity inventory (csi), simplified mcgill pain questionnaire (sf-mpq). explore the relationship between chronic pelvic pain and its postoperative outcomes, as well as in vitro detection results such as preoperative venous blood, intraoperative pathological tissue immunohistochemistry, elisa, transcriptome sequencing in patients with endometriosis.

conduct preoperative and postoperative endometriosis related questionnaire surveys on patients, such as endometriosis health profile-30 (ehp-30), central sensitivity inventory (csi), simplified mcgill pain questionnaire (sf-mpq). follow up will be conducted 1-2 months after surgery. preoperative venous blood from patients with endometriosis and pathological tissue of endometriosis removed during surgery were collected for in vitro testing using immunohistochemistry, elisa, transcriptome sequencing.

Eligibility criteria:
inclusion criteria: * 18 to 50 years old; * endometriosis diagnosed through previous surgery (confirmed solely by visual or histopathological examination), endometriosis discovered through imaging examination, deep infiltrating nodules discovered through palpation or imaging examination, and clinically suspected endometriosis; * no history of migraine or tension headaches; * no history of mental illness (such as restless leg syndrome, chronic fatigue syndrome, fibromyalgia, anxiety or panic attacks, depression). exclusion criteria: * postmenopausal state (spontaneous or surgical); * previous hysterectomy and/or bilateral salpingo oophorectomy (prior to preoperative visit); * the patient or authorizer refuses.

Keywords: chronic pelvic pain endometriosis